Amplia Therapeutics (ASX:ATX), which is developing approaches for the treatment of cancer and fibrosis, has announced that an abstract describing its ACCENT clinical trial of AMP945 in first-line patients with advanced pancreatic cancer has been accepted for presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer.
The conference will be held in Boston in September.
The presentation will be entitled 'Rationale for the use of pulsed rather than continual dosing of the novel Focal Adhesion Kinase inhibitor AMP945 in pancreatic cancer' and will describe the scientific rationale and clinical trial design for ACCENT.
The trial is currently open for recruitment and has been registered on ClinialTrials.gov with an identifier number of NCT05355298.
“The AACR special topic meetings attract the world’s leading cancer researchers who are working at the cutting edge of cancer research and new drug development. We’re delighted to have Amplia’s work accepted for presentation in this forum and expect it will raise awareness in the global clinical community of AMP945 and its potential in this devastating cancer,” said CEO Dr John Lambert